Prostate specific antigen (PSA) is the main secretory

Similar documents
Some prostatic diseases

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT

Prostate Overview Quiz

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Title: The Use of Prostate-Specific Antigen in Prostate Cancer Diagnostics

Prostate Cancer. David Wilkinson MD Gulfshore Urology

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

Definition Prostate cancer

THE UROLOGY GROUP

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER

THE UROLOGY GROUP

Prostate Health PHARMACIST VIEW

An Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

Determination of the Association of Urine Prostate Specific Antigen Levels with Anthropometric Variables in Children Aged 5-14 Years

Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

All about the Prostate

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Diagnosis and management of prostate cancer in the

TOPICS FOR DISCUSSION

Chapter 7. Male Reproductive System. Copyright 2018 Elsevier Inc. All rights reserved.

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for

Benign Prostatic Hyperplasia (BPH):

1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)

Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia

A USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW

Management of LUTS after TURP and MIT

Elements for a Public Summary

The Enlarged Prostate Symptoms, Diagnosis and Treatment

Radical cystectomy is the standard procedure for the. rezime ...

The prostate can be affected by three conditions that may cause problems for men as they get older.

Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017

Questions and Answers About the Prostate-Specific Antigen (PSA) Test

Controversies in Prostate Cancer Screening

(dutasteride/tamsulosin) For the treatment of Benign Prostatic Hyperplasia (BPH)

Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

OMPRN Pathology Matters Meeting 2017

PSA and the Future. Axel Heidenreich, Department of Urology

Diagnosis, pathology and prognosis including variant pathology

Testosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

PSA is rising: What to do? After curative intended radiotherapy: More local options?

Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144

Prostate Gland Disorders

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma

Does TRT Induce Prostate Cancer?

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy

Testosterone and the Prostate

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

How to detect and investigate Prostate Cancer before TRT

Overview. What is Cancer? Prostate Cancer 3/2/2014. Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014

PCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer

When to worry, when to test?

Chapter 18 Development. Sexual Differentiation

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.

Benign prostatic hyperplasia (BPH) is a term that

2. Which male target tissues respond to testosterone, and which require dihydrotestosterone?

PET imaging of cancer metabolism is commonly performed with F18

FAILURE IS NOT AN OPTION HOPE IS NOT A PLAN

Prostate-Specific Antigen (PSA) Test

ACCME/Disclosures. Cribriform Lesions of the Prostate. Case

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

MODULE 3: BENIGN PROSTATIC HYPERTROPHY

PROSTATE CANCER CONTENT CREATED BY. Learn more at

Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality

2011 PROSTATE BRACHYTHERAPY STUDY

Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends

Saving. Kidneys. Benign Prostate Disease

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS

Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery

HIGH MORTALITY AND POOR SURVIVAL OF MEN WITH PROSTATE CANCER IN RURAL AND REMOTE AUSTRALIA

Ductal adenocarcinoma of the prostate: A clinicopathological study

Quality of Life with an Aging Prostate: The Sperling Prostate Center Protocol. Dan Sperling, MD, DABR The Sperling Prostate Center Delray Beach, FL

PSA Screening and Prostate Cancer. Rishi Modh, MD

Prostate Cancer. What Are the Risk Factors? Prostate cancer is the second leading cancer that causes death to men in the U.S.

Chapter 18: Glossary

Prostate Cancer Screening Guidelines in 2017

Subject: Temporary Prostatic Stent and Prostatic Urethral Lift

Introduction. Growths in the prostate can be benign (not cancer) or malignant (cancer).

Chapter 2. Understanding My Diagnosis

They Do Look Alike : Mimics of Prostate Cancer in Biopsy Samples

MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH

Prostate Biopsy Michael Holmes. FRACS (Urology)

4 th Year Urology Core Objectives Keith Rourke (Revised June 1, 2007)

10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION

Controversy Surrounds Question of Who Needs to be Treated for Prostate Cancer No One Size Fits All Diagnosis or Treatment

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT

[PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK

About the authors Dr S. Larry Goldenberg Dr Tom Pickles Dr Kim N. Chi

Transcription:

/STRU^NI RAD UDK 616.65-006-07-089 DOI: 102298 /ACI0902017P Urinary PSA level and relative tumor volume after... T. Pej~i} 1, J. Had i-djoki} 2, B. Markovi} 3, D. Dragi}evi} 1, B. Gli{i} 4, N. Lali} 4, M. A}imovi} 1, Z. D ami} 1, R. Radosavljevic 5 1 Clinical Center of Serbia, Urological Clinic, Belgrade 2 Serbian Academy of Sciences and Arts, Belgrade 3 Clinical Center of Serbia, Institute for Radiology, Belgrade 4 Clinical Center of Serbia, Institute for Medical Biochemistry, Belgrade 5 Clinical Center of Serbia, Institute for Pathology, Belgrade, Objectives: To estimate the ratio between urinary prostate specific antigen (upsa) and tumor volume after. Methods: From 2000 to July 2008, upsa concentration was determined in 60 patients with clinically organ-confined prostate cancer (PCa). All patients underwent six-area transrectal ultrasound (TRUS) - guided biopsy, with at least 12 biopsy cores. Single pathologist determined tumor grade (G), Gleason score (GS), the percentage of tumor infiltration (% TI) and the percentage of positive cores (% PC) in all biopsy cores. Additionally, relative tumor-biopsy volume (RTV) was calculated by multiplying % PC, % TI and prostate ultrasound-derived volume (Vol). Forty-one patients underwent retropubic radical prostatectomy (RRP), while 19 patients underwent radiation therapy. Results: Average upsa was 308.6+311.9 ng/ml (range 0.06-988 ng/ml), average PSA was 9.7+ 5.5 ng/ml (range 1.2-24.3 ng/ml), tumor grade 1.7+ 0.8, Gleason score 5.2 + 1.3, the percentage of tumor infiltration 27.6+21.8 %, and the percentage of positive cores, 52.2+30.7 %. Average RTV was 6.3+ 8.4 ml (0.29-56 ml). All patients were divided in two groups: I, with RTV 4 ml and II, with RTV = 4 ml. The patients with RTV 4 ml had lower G (1.4 0.6 vs. 2.1+0.8, p=0.0002), lower GS (4.5+1 vs. 5.8+1.3, p=0.003) and higher upsa (389.4+340.8 vs. 193.1 +229.7, p=0.014). There were no differences in serum PSA levels between the groups. Conclusion: Relative tumor-biopsy volume (RTV) is useful parameter in the preoperative assessment of tumor volume. Patients with higher RTV had significantly higher G and GS. However, these patients had significantly lower upsa. This phenomenon rezime could be the consequence of compromised PSA drainage from the peripheral zone of the prostate, caused by the tumor. Key words: Prostate cancer, prostate specific antigen, tumor volume, urinary PSA. INTRODUCTION Prostate specific antigen (PSA) is the main secretory product of the prostate gland. The physiological function of PSA is liquefaction of seminal coagulum; this process is crucial for the deliberation of spermatozoa from the seminal gel and their progressive movement. The natural reason for the transfer of PSA molecules from prostatic glands to the blood is not clearly understood. However, this proteolytic enzyme is successfully inactivated in the blood by serine protease inhibitors, alpha-2 macroglobulin (A2M) and antichymotripsine (ACT). The concentration of PSA in the prostatic tissue is 0.01-0.08 mg/ml and it is similar in the normal prostatic tissue, benign prostatic hyperplasia (BPH) and prostate cancer (PCa). The synthesis of PSA is dihydrotestosterone (DHT) dependent 1. After entering the epithelial cell, androgens react with 5-alpha reductase, which converts them into more potent hormone, DHT. The molecules of DHT bind to androgen receptor and enter the nucleus. In the nucleus, DHT-androgen receptor complex stimulates the transcription of various genes, for the synthesis of PSA, growth factors and other proteins 2. After the synthesis, PSA molecules are contained in prostatic secretory granules (PSG), which discharge their content out from the cell 3.

18 T. Pejcic et al. ACI Vol. LVI Following that, PSA molecules leak through prostatic ducts to the prostatic urethra, where they collect, until the next micturition or ejaculation happens. Central and transition zone ducts enter the prostatic urethra at the sharp angle, lateral to the verumontanum. Peripheral zone ducts enter the urethra perpendicularly, along the distance between verumontanum and distal urethral sphincter. Ductal drainage of the prostatic secretions can be compromised in the presence of infection, prostatic calculi and the cancer. Additional PSA molecules are secreted diffusely, along entire urethra, from so-called minor prostatic glands (MPG). All MPG are made of prostatic glands, or of prostatic and mucinous epithelium. Some authors believe that these glands could be responsible for persistent PSA levels after radical prostatectomy 4. It seems that MPG represent evolutionary remnant. Namely, early mammals, that appeared 65 million years ago, probably had primitive prostate consisted of disseminated prostatic glands in the urethra, so-called disseminated prostate 5. In the present time, small, microscopic disseminated prostates can be seen in whales and dolphins, and larger one in other mammals, like boar, ram and bull; the mammals on the higher evolutionary position, including primates, developed compact organ 6,7,8. In primates and humans, these glands probably provide diffuse presence of PSA in the urethra and, maybe, take place in the cleansing of the urethra after the ejaculation. All PSA molecules detected in the urine, are washedout from the urethra during the micturition. Namely, 32.9 kda heavy PSA molecule, cannot pass the glomerular membrane; it is proved that no PSA can be detected in the urine from ileal conduits, or nephrostomy catheters 9,10. In 1992, DeVere White 11 reported that average upsa concentration in the group of BPH patients was 216 ng/ml. Later on, it was found that the average upsa in the PCa group was 915 ng/ml in the first stream and 246 ng/ml in the middle stream 12,13. In the recent works, it is found that patients with BPH have higher upsa than the patients with PCa (123.2 vs. 52.6 ng/ml. Cut-off value of 150 ng/ml differentiate BPH and PCa with the sensitivity of 92.5%) 14. In addition, in some recent works upsa is used as a marker which reflects total androgen activity. Rising concentration of upsa is the simple method for the detection of early puberty in boys, as well as the test for the detection of androgen insensitivity and inadequate virilization 15. 7 6 5 4 3 2 1 0 RTV < 4 RTV = 4 G FIGURE 1. TUMOR GRADE (G) AND GLEASON SCORE (GS) IN THE GROUP WITH RELATIVE TUMOR-BIOPSY VOL- UME (RTV) < 4 ML, AND IN THE GROUP WITH RTV = 4 ML. 500 400 300 200 100 0 GS RTV < 4 RTV = 4 upsa Volp PSA FIGURE 2. URINARY PSA, PROSTATE VOLUME (VOLP) AND PSA IN THE GROUP WITH RELATIVE TUMOR-BI- OPSY VOLUME (RTV) < 4 ML, AND IN THE GROUP WITH RTV = 4 ML. FIGURE 3. PROSTATIC DUCTAL OBSTRUCTION CAUSED BY TUMOR.

Br. 2 Urinary PSA level and relative tumor volume after 19 TABLE 1 VALUES OF TUMOR GRADE (G), GLEASON SCORE (GS), UPSA, PROSTATE VOLUME (VOLP) AND PSA IN THE GROUP WITH RELATIVE TUMOR-BIOPSY VOLUME (RTV) < 4 ML, AND IN THE GROUP WITH RTV = 4 ML. Group n G GS upsa (ng/ml) Volp (ng/ml) PSA (ng/ml) RTV <4ml 31 1.4+0.6 4.5+1 389.4+340.8 37.2+12.3 9.9+5.9 REV > 4 ml 29 2.1+0.8 5.8+1.4 193.1+229.7 43.7+26.2 9.4+5.2 p 0.002 0.003 0.014 0.11 0.36 Total 60 1.7+0.8 5.1+1.3 308.6+311.9 40.3+20.4 9.7+5.5 It is worthy to note that in some primates upsa rise in the breeding season: in Japanese makaka monkeys, the rise of upsa appears just after the termination of the menstrual bleeding in 16. METHODS From 2000 to July 2008, in Urological Clinic, Clinical Center of Serbia, the concentration of urinary PSA was determined in 60 patients with clinically organconfined prostate cancer (PCa). Prior to curative therapy, all patients underwent six-area TRUS - guided biopsy, with at least 12 biopsy cores. Transrectal ultrasound and TRUS- biopsies were performed on Toshiba- Tosbee machine, with transrectal probe IVE- 506S. Prostate volume was calculated on usual manner: a x b x c x pi/6. Biopsy was performed with 160mm/16G needles, using Gallini or Bard biopsy gun. All patients gave first 70 ml of fresh urine just prior to biopsy. The urine was titrated with NaOH until the ph of 7.5 was reached. Urine samples were spun in the centrifuge at 2000 rpm for 10 minutes. Aliquots of 500 l samples were frozen at -20C and stored. Urinary PSA was determined using IRMA-PSA test, produced in Institute for Nuclear Energy Application (INEP), Zemun, Belgrade. Single pathologist (R.R.) determined tumor grade (G), Gleason score (GS), the percentage of tumor infiltration (% TI) and the percentage of positive cores (% PC) in all biopsy cores. Relative tumor-biopsy volume (RTV) was calculated by multiplying % PC, % TI and prostate volume derived by ultrasound (RTV = % PC x % TI x Vol) Forty-one patients underwent retropubic radical prostatectomy (RRP), while 19 patients underwent radiation therapy. RESULTS Average upsa was 308.6 311.9 ng/ml (range 0.06-988 ng/ml), average PSA was 9.7+5.5 ng/ml (range 1.2-24.3 ng/ml), tumor grade 1.7+0.8, Gleason score 5.2+1.3, the percentage of tumor infiltration 27.6+ 21.8 %, and the percentage of positive cores, 52.2+ 30.7 %. Average RTV was 6.3+8.4 ml (0.29-56 ml). All patients were divided in two groups: I, with RTV 4 ml and II, with RTV = 4 ml. The patients with RTV 4 ml had lower G (1.4+0.6 vs. 2.1+0.8, p=0.0002), lower GS (4.5+1 vs. 5.8+1.3, p=0.003) and higher upsa (389.4 +340.8 vs. 193.1+229.7, p=0.014). There were no differences in serum PSA levels between the groups. (Table 1, Figure 1, 2) DISCUSSION It has been said that PSA is the best and most widely used tumor marker in medicine. Its influence on urology is so great, that some authors differentiate pre-psa and PSA era in the prostate cancer management. Indeed, PSA enabled male population screening and early cancer detection, as well as preoperative staging and postoperative follow-up. It is not completely clear why PSA molecules leak from prostatic ductal system and enter the circulation. However, it is clear that high PSA concentration in seminal plasma is necessary for the liquefaction of the seminal coagulum after the ejaculation. Namely, PSA concentration in seminal plasma is million-time higher than in the blood. In the absence of ejaculations, the synthesis and the secretion of PSA are maintained; these processes depend on testosterone and DHT level. From the other side, the most important source of PSA is the peripheral zone, rich in prostatic glands. Prostatic ducts from the peripheral zone possess wide lumina and wide openings in the prostatic urethra. However, some processes can compromise prostatic drainage. At the first

20 T. Pejcic et al. ACI Vol. LVI place, prostatic tumors, which are the most common in the peripheral zone, can obstruct prostatic ducts. Small tumors can block prostatic drainage in few ducts, but large tumors can completely stop prostatic drainage. In such cases, the majority of PSA molecules that reach the prostatic urethra and urine are of urethral origin. (Figure 3) The term urinary PSA is not completely correct: there are no PSA molecules in the urine from the kidneys to the urinary bladder. In fact, PSA is present only in the urine out of the body, after voiding. Therefore, word that is more correct would be washed-out PSA, or secreted PSA. Nevertheless, today urinary PSA has no the place in the urology that it deserves. The most common reasons for that are the fluctuations in results due to hormonal influences, various biochemical conditions in the urine, the absence of agreement of the best way of collecting the urine, etc. The specificity of this test will surely rise when all these factors would be routinely considered. Using the new parameter- relative tumor-biopsy volume (RTV), it was possible to approximate tumor volume in the cases when pathologist cannot determinate it in the radical prostatectomy specimen, or in the cases that were treated by radiation therapy. Patients with RTV greater than 4 ml had significantly higher tumor grade and Gleason score. This observation agrees with known facts that greater tumors are more aggressive. From the other side, the fact that the patients with RTV = 4 ml had significantly lower upsa than the patients with RTV 4 ml, could be the consequence of compromised PSA drainage from the peripheral zone of the prostate caused by the tumor. CONCLUSION: Urinary PSA, or washed-out PSA, is valuable marker which characteristics are not completely explored. The fact that upsa is significantly lower in the patients with greater prostate tumors gives hope that the researches in the field of urinary PSA have the future. SUMMARY NIVO PSA U URINU I RELATIVNOG VOLUMENA TUMORA POSLE BIOPSIJE PROSTATE Cilj rada: ustanoviti da li postoji odnos izmedju nivoa prostata specifi~nog antigena (PSA) u urinu i zapremine tumora prostate, odredjene na osnovu rezultata biopsije prostate. Materijal i metode: od 2000. godine do jula 2008, kod 60 bolesnika Urolo{ke klinike Klini~kog centra Srbije je odredjivana koncentracija urinarnog PSA (upsa). Kod svih bolesnika je postojao karcinom prostate u klini~kom stadijumu T2, odnosno tumor ograni~en na prostatu. Kod svih bolesnika je uradjena biopsija prostate vodjena transrektalnim ultrazvukom (TRUS- biopsija), iz {est standardnih polja, sa najmanje 12 ise~aka. Kod svih bolesnika je patolog u bioptiranom materijalu odredjivao gradus tumora (G), Glisonov skor (Gleason score, GS), procenat tumorske infiltracije (% TI) i procenat pozitivnih ise~aka (% PC) u materijalu. Osim toga, kod svih bolesnika je posle toga odredjivan relativni volumen tumora posle biopsije (RTV), koji se izra~unava kao proizvod % TI, % PC i zapremine prostate odredjene na TRUS (Volp). Kod 41 bolesnika je uradjena radikalna prostatektomija, a kod 19 zra~na terapija na Institutu za onkologiju i radiologiju u Beogradu. Rezultati: Prose~na koncentracija upsa je iznosila 308.6+311.9 ng/ml, (0.06-988 ng/ml) a prose~na koncentracija PSA je bila 9.7+5.5 ng/ml (1.2-24.3 ng/ml). Prose~an gradus tumora je bio 1.7+0.8,a prose~ni Glisonov skor 5.2+1.3. Prose~na tumorska infiltracija je iznosila 27.6+21.8 %, a procenat pozitivnih ise~aka 52.2+30.7 %. Prose~na vrednost RTV je bila 6.3+8.4 ml (0.29-56 ml). Svi bolesnici su podeljeni u dve grupe: I (RTV 4 ml) i II (RTV? 4 ml). Bolesnici sa RTV 4 ml su imali ni i G (1.4+0.6 prema 2.1+0.8, p=0.0002), ni i Glisonov skor (4.5+1 prema 5.8+1.3, p=0.003) i vi{i upsa (389.4+340.8 vs. 193.1+229.7, p=0.014). Nisu nadjene zna~ajne razlike u kocentraciji serumskog PSA izmedju dve grupe. Zaklju~ak: Relativni volumen tumora posle biopsije (RTV) je koristan parametar za preoperativnu procenu zapremine tumora. U ovoj studiji, bolesnici koji su imali ve}i RTV, imali su i vi{i gradus i Glisonov skor tumora. Sa druge strane, bolesnici sa ve}im RTV su imali zna~ajno ni i upsa. Ovaj fenomen je verovatno posledica prisustva tumora prostate, koji vr{i opstrukciju prostati~nih duktusa i ote ava drena u PSA, uglavnom iz periferne zone prostate. Klju~ne re~i: karcinom prostate, prostata specifi~ni antigen, urinarni PSA, volumen tumora. REFERENCES 1. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. 2009 Feb;1155:43-56. 2. Alonso-Magdalena P, Brossner C, Reiner A, Cheng G, Sugiyama N, Warner M, Gustafsson JA. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. 2009 Feb 24;106(8):2859-63. Epub 2009 Feb 5.

Br. 2 Urinary PSA level and relative tumor volume after 21 3. Cohen RJ, Garett K, Golding JL, et al.: Epithelial differentiation of the lower urinary tract recognition of the minor prostatic glands. Hum Pathol 2002;33(9):905-9 4. Oesterling JE, Tekchandani AH, Martin SK, et al: The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J urol 1996;155(5):1658-60 5. Coffey DS. Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Urology. 2001 Apr;57(4 Suppl 1):31-8. 6. De Guise S, Bisaillon A, Seguin B, et al.. The anatomy of the male genital system of the beluga whale, Delphinapterus leucas, with special reference to the penis. 1994 Sep;23(3):207-16. 7. Kaleczyc J, Majewski M, Calka J. et al. Adrenergic innervation of the epididymis, vas deferens, accessory genital glands and urethra in the boar. 1993;31(3):117-23. 8. M. Nicaise, H. Lauwers, P. Simoens. Morphological Study of the Development of the Disseminate Prostate in Intact and Castrated Male Pigs Aged Two to Six Months. Acta Anatomica 1991;141:335-347 9. Shibata K, Kajihara J, Kato K, et al: Purification and characterization of prostate specific antigen from human urine. Biochim Biophys Acta 1997;1336(3):425-33 10. Kabalin JN, Hornberger JC: Prostate specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology,1991; 37:308-310 11. DeVere White RW, Meyers FJ, Soares SE, Miller DG, Soriano TF: Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. J Urol 1992;147(3 Pt 2):947-51 12. Iwakiri J, Granbois K, Wehner N, Graves HC, Stamey TA: An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 1993;149(4):783-6 13. Takayama TK, Vessella RL, Brawer MK, True LD, Noteboom J, Lange PH: Urinary prostate specific antigen levels after radical prostatectomy. J Urol 1994;151(1):82-7 14. Bolduc S, Lacombe L, Naud A, Gregoire M, Fradet Y, Tremblay RR. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/ml and 10 ng/ml. Can Urol Assoc J. 2007 Nov;1(4):377-81. 15. Sato I, Yoshikawa A, Shimizu K, Ishiwari A, Mukai T, Iwamoto T. Urinary prostate-specific antigen is a noninvasive indicator of sexual development in male children. J Androl. 2007 ;28: 155 157 16. Sato I, Yoshikaea A, Ishiwari A, Shimizu K. Seasonal changes in urinary prostate-specific antigenic activity in male Japanese macaques (Macaca fuscaa fuscata). 2007 Nov-Dec;28(6):821-6. Epub 2007 Jul 3.